When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Disseminated intravascular coagulation

Última revisão das evidências: 9 Jun 2026
Última atualização do tópico: 08 Jul 2026

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presence of underlying disorders
  • oliguria, hypotension, or tachycardia
  • delirium or coma
  • petechiae, ecchymosis, oozing, or hematuria
Detalhes completos

Outros fatores diagnósticos

  • purpura fulminans, gangrene, or acral cyanosis
Detalhes completos

Fatores de risco

  • sepsis/severe infection
  • severe organ destruction or failure
  • shock
  • obstetric disorders or complications
  • solid tumors and hematologic malignancies
  • severe toxic or immunologic reactions
  • major vascular disorders (large aortic aneurysms or giant hemangiomas)
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • platelet count
  • prothrombin time (PT)/INR
  • fibrinogen
  • D-dimer/fibrin degradation products
  • activated partial thromboplastin time (aPTT)
  • imaging studies or other tests
Detalhes completos

Investigações a serem consideradas

  • thrombin time
  • antithrombin
Detalhes completos

Algoritmo de tratamento

AGUDA

low bleeding risk

high bleeding risk or active bleeding

CONTÍNUA

chronic disseminated intravascular coagulation

Colaboradores

Autores

Jerrold Levy, MD, FAHA, FCCM

Emeritus Professor of Anesthesiology, Critical Care, and Surgery (Cardiothoracic)

Duke University School of Medicine

Adjunct Professor

Department of Pathology & Laboratory Medicine

Faculty of Medicine at the UBC Vancouver Campus

Durham, NC

Declarações

JHL receives honoraria for research advisory steering committees for Bayer, Grifols, Octapharma, and Werfen that are unrelated to considerations for disseminated intravascular coagulation.

Toshiaki Iba, MD

Department of Emergency and Critical Care Medicine

Juntendo University

Japan

Declarações

TI declares that he has no competing interests.

Marcel Levi, MD, PhD

Professor of Medicine

University College London Hospitals NHS Foundation Trust

London

UK

Declarações

ML declares that he has no competing interests.

Agradecimentos

Dr Jerrold Levy, Dr Toshiaki Iba, and Dr Marcel Levi would like to gratefully acknowledge Dr Frank G. Zavisca and Dr Haibo Wang, previous contributors to this topic.

Declarações

FGZ and HW declare that they have no competing interests.

Revisores

Pavan Bendapudi, MD

Assistant Professor of Medicine

Harvard Medical School

Boston, MA

Declarações

PB declares that he has no competing interests.

Cheng-Hock Toh, MB, ChB, MD, FRCP, FRCPath

Professor of Haematology

University of Liverpool

Liverpool

UK

Declarações

CHT is an author of a reference cited in this topic.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

Squizzato A, Gallo A, Levi M, et al. Underlying disorders of disseminated intravascular coagulation: communication from the ISTH SSC subcommittees on disseminated intravascular coagulation and perioperative and critical care thrombosis and hemostasis. J Thromb Haemost. 2020 Sep;18(9):2400-7.Texto completo  Resumo

Iba T, Helms J, Connors JM, et al. The pathophysiology, diagnosis, and management of sepsis-associated disseminated intravascular coagulation. J Intensive Care. 2023 May 23;11(1):24.Texto completo  Resumo

Iba T, Levi M, Thachil J, et al. Disseminated intravascular coagulation: the past, present, and future considerations. Semin Thromb Hemost. 2022 Nov;48(8):978-87. Resumo

Levi M, Scully M. How I treat disseminated intravascular coagulation. Blood. 2018 Feb 22;131(8):845-54.Texto completo  Resumo

Levi M, Toh CH, Thachil J, et al. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 Apr;145(1):24-33.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Diagnósticos diferenciais

    • Severe liver failure
    • Heparin-induced thrombocytopenia
    • Vitamin K deficiency
    Mais Diagnósticos diferenciais
  • Diretrizes

    • The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition
    • Supportive management strategies for disseminated intravascular coagulation. An international consensus
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Disseminated intravascular coagulation

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal